vs
Side-by-side financial comparison of FIRST MID BANCSHARES, INC. (FMBH) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $88.2M, roughly 1.5× FIRST MID BANCSHARES, INC.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 3.4%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 5.0%).
First Mid Bancshares Inc. is a U.S.-headquartered regional financial services holding company. It provides full-range retail and commercial banking products, wealth management, insurance solutions, and agricultural financing, mainly serving individual consumers, small and medium-sized enterprises, and agricultural clients across multiple Midwestern states including Illinois, Missouri, and Indiana.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
FMBH vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $88.2M | $129.7M |
| Net Profit | $23.7M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | 34.0% | -25.0% |
| Net Margin | 26.8% | — |
| Revenue YoY | 3.4% | 73.4% |
| Net Profit YoY | 23.5% | — |
| EPS (diluted) | $0.98 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $88.2M | $129.7M | ||
| Q3 25 | $89.3M | $164.9M | ||
| Q2 25 | $87.5M | $114.4M | ||
| Q1 25 | $84.3M | $81.7M | ||
| Q4 24 | $85.3M | $74.8M | ||
| Q3 24 | $80.6M | $62.9M | ||
| Q2 24 | $79.2M | $54.1M | ||
| Q1 24 | $79.9M | $41.4M |
| Q4 25 | $23.7M | — | ||
| Q3 25 | $22.5M | $25.7M | ||
| Q2 25 | $23.4M | $-12.8M | ||
| Q1 25 | $22.2M | $-41.2M | ||
| Q4 24 | $19.2M | — | ||
| Q3 24 | $19.5M | $-54.8M | ||
| Q2 24 | $19.7M | $-70.4M | ||
| Q1 24 | $20.5M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | 34.0% | -25.0% | ||
| Q3 25 | 32.2% | 15.1% | ||
| Q2 25 | 34.4% | -11.1% | ||
| Q1 25 | 33.4% | -52.2% | ||
| Q4 24 | 29.7% | -81.2% | ||
| Q3 24 | 31.5% | -89.3% | ||
| Q2 24 | 33.7% | -125.1% | ||
| Q1 24 | 33.7% | -336.5% |
| Q4 25 | 26.8% | — | ||
| Q3 25 | 25.2% | 15.6% | ||
| Q2 25 | 26.8% | -11.1% | ||
| Q1 25 | 26.3% | -50.4% | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 24.2% | -87.1% | ||
| Q2 24 | 24.9% | -130.1% | ||
| Q1 24 | 25.6% | -328.9% |
| Q4 25 | $0.98 | $0.04 | ||
| Q3 25 | $0.94 | $0.28 | ||
| Q2 25 | $0.98 | $-0.14 | ||
| Q1 25 | $0.93 | $-0.47 | ||
| Q4 24 | $0.81 | $-0.71 | ||
| Q3 24 | $0.81 | $-0.70 | ||
| Q2 24 | $0.82 | $-0.91 | ||
| Q1 24 | $0.86 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $93.0M |
| Total DebtLower is stronger | $354.5M | — |
| Stockholders' EquityBook value | $958.7M | $114.8M |
| Total Assets | $8.0B | $605.2M |
| Debt / EquityLower = less leverage | 0.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.0M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | — | $75.2M | ||
| Q1 25 | — | $61.9M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $36.4M | ||
| Q2 24 | — | $32.3M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | $354.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $958.7M | $114.8M | ||
| Q3 25 | $932.2M | $73.6M | ||
| Q2 25 | $894.1M | $32.7M | ||
| Q1 25 | $870.9M | $32.8M | ||
| Q4 24 | $846.4M | $59.1M | ||
| Q3 24 | $858.5M | $-30.5M | ||
| Q2 24 | $813.6M | $15.1M | ||
| Q1 24 | $798.0M | $74.1M |
| Q4 25 | $8.0B | $605.2M | ||
| Q3 25 | $7.8B | $538.6M | ||
| Q2 25 | $7.7B | $555.3M | ||
| Q1 25 | $7.6B | $548.8M | ||
| Q4 24 | $7.5B | $594.1M | ||
| Q3 24 | $7.6B | $504.4M | ||
| Q2 24 | $7.6B | $551.1M | ||
| Q1 24 | $7.7B | $663.5M |
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $130.9M | $60.7M |
| Free Cash FlowOCF − Capex | $124.0M | — |
| FCF MarginFCF / Revenue | 140.6% | — |
| Capex IntensityCapex / Revenue | 7.8% | — |
| Cash ConversionOCF / Net Profit | 5.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | $207.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.9M | $60.7M | ||
| Q3 25 | $33.0M | $14.3M | ||
| Q2 25 | $7.7M | $5.0M | ||
| Q1 25 | $47.9M | $-42.2M | ||
| Q4 24 | $124.4M | $-35.7M | ||
| Q3 24 | $33.1M | $-42.5M | ||
| Q2 24 | $24.0M | $-40.2M | ||
| Q1 24 | $29.0M | $-119.0M |
| Q4 25 | $124.0M | — | ||
| Q3 25 | $31.9M | $14.2M | ||
| Q2 25 | $6.0M | — | ||
| Q1 25 | $46.0M | — | ||
| Q4 24 | $119.5M | — | ||
| Q3 24 | $32.0M | — | ||
| Q2 24 | $22.9M | $-40.3M | ||
| Q1 24 | $27.6M | — |
| Q4 25 | 140.6% | — | ||
| Q3 25 | 35.8% | 8.6% | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 54.5% | — | ||
| Q4 24 | 140.0% | — | ||
| Q3 24 | 39.7% | — | ||
| Q2 24 | 28.9% | -74.5% | ||
| Q1 24 | 34.5% | — |
| Q4 25 | 7.8% | — | ||
| Q3 25 | 1.2% | 0.1% | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 5.8% | — | ||
| Q3 24 | 1.4% | 0.0% | ||
| Q2 24 | 1.4% | 0.2% | ||
| Q1 24 | 1.9% | 0.0% |
| Q4 25 | 5.53× | — | ||
| Q3 25 | 1.47× | 0.56× | ||
| Q2 25 | 0.33× | — | ||
| Q1 25 | 2.16× | — | ||
| Q4 24 | 6.49× | — | ||
| Q3 24 | 1.70× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 1.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FMBH
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
